The gene for human nuclear NAD' ADPribosyltransferase [NAD+:poly(adenosine diphosphate Dribose) ADP-D-ribosetransferase, EC 2.4.2.30; pADPRTJ was localized to chromosome 1 at q41-q42 by in situ hybridization with a pADPRT-specific cDNA probe. Expression of a pAD-PRT cDNA under control of the lac promotor in Escherichia coli induces the synthesis of a group of related proteins that were immunoreactive with pADPRT antibody and that had catalytic properties very similar to those of the human enzyme. Purification of this enzymatic activity was performed essentially as described for the human enzyme. The Ki, pH optimum, optimal reaction temperature, and inhibition by 3-aminobenzamide and 3-methoxybenzamide were found to be similar for the recombinant and the human enzymes. (6) (7) (8) (9) . These cDNAs provide the means to investigate structure and function of the gene for pADPRT.
tially as described for the human enzyme. The Ki, pH optimum, optimal reaction temperature, and inhibition by 3-aminobenzamide and 3-methoxybenzamide were found to be similar for the recombinant and the human enzymes. The purified recombinant enzyme consists of two major proteins of Mr 99,000 and Mr 89,000. Both proteins show pADPRT activity in activity gel analysis with [32PJNAD' as substrate. Microsequencing of these two proteins isolated by denaturing gel electrophoresis and deletion mutagenesis of the pADPRT expression plasmid shows that the Mr 99,000 and Mr 89,000 proteins derive from initiation of translation at internal translational start signals located within the pADPRT cDNA.
Nuclear NAD' ADP-ribosyltransferase [NAD+:poly(adenosine diphosphate D-ribose) ADP-D-ribosetransferase, EC 2.4.2.30; pADPRT] catalyzes the transfer of ADP-ribose moieties from NAD' to proteins, elongation of poly(ADPribose) chains, and chain branching. Acceptor molecules for poly(ADP-ribose) include chromatin-associated proteins like histones, topoisomerases I and II, DNA ligases I and II, DNA polymerases a and 1B, endonuclease, and terminal deoxynucleotidyltransferase as well as pADPRT itself. The enzymatic activity of these proteins is regulated by ADP-ribosylation. Studies on the function of this modulation suggest a relationship between ADP-ribosylation and important processes such as chromatin organization, cell proliferation, cellular differentiation, and recovery of cells from DNA damage. pADPRT activity is strongly induced by DNA strand breaks produced by the incision step of DNA repair after treatment by various noxious agents (such as ultraviolet irradiation, alkylation, or ionizing radiation). During this process, NAD' is consumed in a large amount, and this leads to a measurable decrease in the intracellular level of NAD'. Suppression of pADPRT activity by specific inhibitors potentiates the lethal effects of noxious agents (for recent reviews, see refs 1-4) .
In cells from patients suffering from Fanconi anemia, a hereditary disease associated with defective recovery from cellular damage by the above agents, this NAD' consumption is reduced (5) . A possible reason for this diminished NAD' consumption could be a defect in the ADPribosylation reaction. This potential role of defective ADPribosylation in pathogenesis of Fanconi anemia and its importance in DNA repair, cellular differentiation, cell proliferation, and tumorigenic transformation prompted us and others to purify pADPRT and to clone its cDNA from human tissue (6) (7) (8) (9) . These cDNAs provide the means to investigate structure and function of the gene for pADPRT.
In this report, we describe the localization of the pADPRT gene on chromosome 1 at q41-q42 by in situ hybridization with a partial pADPRT cDNA clone. Furthermore, the expression ofa 3.2-kilobase (kb) pADPRT cDNA fragment in Escherichia coli, produced an active enzyme. This recombinant human pADPRT shows enzymatic properties that are very similar to those of the enzyme prepared from human placenta and is in keeping with the known structure-function relationships of this enzyme. Our recombinant human pAD-PRT was purposely engineered to lack the N-terminal DNA binding domain of the authentic pADPRT to increase the probability of obtaining a purified protein capable of forming crystals amenable to structural analysis. The ability to produce purified recombinant pADPRT in large quantities and with defined deletions or mutations should greatly facilitate further studies of its structure and function.
MATERIALS AND METHODS Chemicals and Enzymes. Restriction endonucleases and the Klenow fragment ofDNA polymerase I were purchased from Boehringer Mannheim. pBluescript KS(+) and enzymes for the exo/mung DNA sequencing system were from Stratagene (La Jolla, CA). Radioactive-isotope-labeled compounds were purchased from Amersham.
Nucleotide Sequence Determination. All DNA manipulations were done by standard protocols (10) . cDNA derived from HeLa mRNA was inserted in phage Agtll (11) and in the human expression vector pcDVl (12) to get reliable cDNA libraries (6, 13) . pADPRT-specific inserts were subcloned into pBluescript KS(+) vectors. Both strands of the cDNA fragments were sequenced with several universal primers and, in critical regions, with oligonucleotides (17-mer) corresponding to previously sequenced regions by the doublestrand sequencing method (14) .
A human genomic library prepared from human liver DNA in pcos2EMBL (15) Chromosomal in Situ Hybridization. In situ hybridization of the pADPRT probe (the 2.1-kb EcoRI cDNA fragment of clone G8; see ref. 6 ) to metaphase and prometaphase chromosomes was performed as described in detail (16) . Briefly, chromosomes were prepared from BrdUrd-synchronized lymphocytes (17) to obtain prometaphase chromosomes and to achieve high-resolution banding. Hybridization of the 3H-labeled probe (2-3 x 107 cpm/,g of DNA, randomprimed labeling; see ref. 18 ) to the chromosomes was done essentially by following established techniques (19) . The location of the hybridization probe was detected as silver grains produced in the photographic emulsion (10 days exposure time). G-banding was performed after the in situ hybridization procedure (16, 20) . Clones Hz2J, Hz22, Hz23, and Hz24. Additional potential translation initiation sites were removed from clone Hzl9 or Hz2O by deletion of various restriction fragments (see Fig. 4 Upper). Numbering is relative to the lacZ initiation site in clone Hz2O. In clone Hz21, nucleotides 57-384 including codon ATG at position 298 (initiation site a in Fig. 1 (20 g ) were thawed in 100 ml of extraction buffer (23) , the suspension was passed three times through a French Pressure cell (Aminco) at 12,000 pounds per square inch (1 psi = 6.89 kPa), and the homogenate was centrifuged at 14,000 x g for 5 min. The purification procedure as well as the pADPRT assay were both carried out essentially as described (23) .
Immunoblot Analysis. Samples from all purification steps were analyzed as described (6) . Affinity-purified rabbit antigoat IgG-horseradish peroxidase conjugate (Dako, Santa Barbara, CA) was used as a second antibody. Biotinylated molecular markers were detected by adding Streptavidinperoxidase (Sigma, Munich) at 0.3 pgg/ml to the second antibody solution.
Activity Gel Analysis. This analysis was done by the method of Scovassi et al. (24) as described (25) .
Protein Sequencing. The affinity-purified fraction was separated on a 10%o gel by NaDodSO4/PAGE (26) . The protein bands were electrotransferred onto a siliconized glass fiber sheet (Glassybond, Biometra, Gottingen) essentially as described (27) . Blotting was performed at room temperature at 200 mA for 5 hr by using a transfer buffer containing 5% methanol. After Coomassie blue staining of the sheets, the stained bands were excised and placed directly in a gas-phase sequencer with a phenythiohydantoin analyzer (Applied Biosystems 120A).
RESULTS AND DISCUSSION
Chromosomal Localization of the pADPRT Gene. A tritiated probe was hybridized in situ to prometaphase chromosomes to define the chromosomal region containing the gene for pADPRT. After autoradiography, silver grains were scored in 60 cells as represented in Fig. 2 . The peak of grain distribution appeared at a single site, namely bands q41-q42 of chromosome 1 (representing 25% of total grains). Of the 60 §The sequence reported in this paper is being deposited in the EMBL/GenBank data base (accession no. J04558).
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Biochemistry metaphases analyzed 21 (35%) were labeled at this specific site. Background labeling was low. The number of grains was slightly above background at only one additional site (14q22) with the hybridization conditions used. This is in agreement with the result of Southern analysis of DNA from cell hybrids, which showed that pADPRT-specific sequences segregate concordantly with chromosomes 1 and 14 (28) . Localization of a pADPRT pseudo gene on chromosome 13 (28) could not be confirmed by our in situ hybridization. This might be due to our use of only a 2.1-kb fragment of the pADPRT cDNA.
Sequence of Human pADPRT cDNA from HeLa Cells. We have been able to isolate several pADPRT-specific cDNA clones by screening of our Agtll and pcDV1 cDNA libraries prepared from HeLa mRNA with antibodies against pAD-PRT and specific oligonucleotides, respectively (6, 29) . The largest cDNA inserts from both libraries (2.1 and 3.2 kb, respectively) were subcloned and sequenced. By comparing our HeLa pADPRT cDNA sequence and our data obtained by sequencing pADPRT-specific clones from a genomic library prepared from human liver (unpublished data) with the published pADPRT cDNA sequences from simian virus 40-(SV40)-transformed fibroblasts (8, 28) , untransformed fibroblasts (7), and placenta (7), seven sequence differences causing changes in the amino acid sequence were detected in the coding region (Table 1) . We have verified our results by sequencing the critical regions in both directions in several independent clones, using synthetic oligonucleotides as primers. The published differences are most likely sequencing or cloning artifacts, especially since different sequences for the same plasmids have been determined (8, 28) . There is no apparent difference in the pADPRT cDNA sequence between normal and transformed cells in the coding region. However, the 3' untranslated sequence has different lengths in various cell types. In untransformed cells the poly(dA) tract begins at nucleotide 3697 (7), whereas in SV40-transformed fibroblasts and in HeLa cells, nucleotide 3501 is used as the polyadenylylation site (8, 28 (Fig. 3A, lane 2) . (7) and placenta (7).
tGenomic DNA from human liver.
These proteins of Mr 99,000 and Mr 89,000 and, additionally, the fusion protein of Mr 109,000 and some other proteins in lower quantities were also detected by immunoblot analysis of the crude extract with affinity-purified antibodies against human pADPRT (Fig. 3B, lane 2) . Activity gel analysis shows that these polypeptides possess strong pADPRT activity (Fig. 3C, lane 2) . Additionally, a strong pADPRT activity appeared at Mr 64,000, and some weaker signals appeared at Mr 70,000 and below Mr 50,000. As a control, no pADPRTrelated proteins were detected in untransformed cells in activity gel analysis or in immunoblot experiments (Fig. 3 B  and C, lane 1) .
Purification of Recombinant pADPRT. Recombinant pAD-PRT protein was purified from E. coli JM 109 cells transformed with Hz2O in a yield of 1 mg from 20 g ofwet cell mass. After disruption of the cells in a French Pressure cell, the pADPRT activity was purified exactly like the placental enzyme (23) . The enzymatic activity formed a sharp symmetrical peak in each column profile during the purification. The result of this procedure was a fraction consisting of two major proteins and some minor components (Fig. 3A, lanes  3-5) .
Immunoblot (Fig. 3B, lanes 3-5) and activity gel analysis (Fig. 3C, lanes 2 and 3) showed that these proteins are enriched during the entire purification procedure, react with pADPRT-specific antibodies, and exhibit pADPRT activity. Comparison of the enzymatic properties of pADPRT from human placenta with those of the recombinant enzyme showed that Km, pH optimum, optimal temperature, and inhibition by 3-methoxybenzamide are almost identical (data not shown). However, it was not possible to stimulate this activity with nicked DNA. This was expected because the first 67 amino acids from the DNA binding domain (7) in the N-terminal region of the pADPRT protein are missing in our recombinant protein. DNA binding domains of several proteins show common structures called zinc fingers (30) . From the pADPRT cDNA sequence, the potential to form two such zinc fingers can be localized in the N-terminal region of the protein (7, 8, 28 ). The first of these putative zinc fingers is missing in the recombinant pADPRT. The Vm. of the recombinant enzyme is reduced relative to authentic pAD- PRT, even in an affinity-purified preparation. Obviously, the DNA binding domain at the N-terminal end of pADPRT controls the efficiency of the enzyme reaction.
E. coli Uses Several Translation Initiation Sites. Plasmid Hzl9 (Fig. 4 Upper) was transformed into E. coli JM 109 to decide whether the two purified polypeptides derived from proteolytic degradation or whether they stem from some other origin. This plasmid contains an in-frame stop codon 28 codons downstream of the lacZ translation initiation site. However, instead of directing the synthesis of only a Mr 2500 peptide, lower levels of the same high-molecular-weight immunoreactive material as was produced with the plasmid Hz2O were synthesized, with the exception of the Mr 109,000 protein (Fig. 4 Lower, lane 2). The stop codon in Hzl9 (UGA) cannot be suppressed by the E. coli strain JM 109 (supE = UAG). Since the stop codon in Hzl9 apparently does not block further protein synthesis, there possibly are additional translational start signals in the pADPRT mRNA that are recognized in E. coli. Inspection of the cDNA sequence revealed four such potential initiation codons (a, b, c, and d in Fig. 4 Upper), all preceded by potential ribosome binding sites (ref. 31 ; Fig. 1 ). Initiation of translation from these sites should lead to proteins of Mr 99,000, Mr 89,000, Mr 64,000, and Mr 45,000, respectively. The molecular weight of the proteins detected by pADPRT antibodies in crude extracts of Hzl9-transformed E. coli JM 109 cells correlate very well with these predicted molecular weights (Fig. 4 Lower). An additional argument against proteolytic cleavage comes from the observation that transformation of a lon proteasedeficient E. coli mutant (strain SG4044) with the plasmid Hzl9 shows the identical protein pattern in the immunoblot (Fig. 4 Lower, lane 1) . Furthermore, a number of deletions of the potential initiation sites in the pADPRT cDNA (Fig. 4 Upper) were analyzed in the same way (Fig. 4 Lower) . In E. coli transformants with plasmids Hz2O (lane 3), Hz21 (lane 4), and Hz22 (lane 5), translation begins at the lacZ translational start signal at the 5' end of the mRNA. In these cells, a large number of pADPRT-specific proteins was produced, appearing as strong bands in the immunoblot at the predicted molecular weight. Additionally, a number of weaker bands react with the pADPRT antibodies. The origin of these polypeptides is unclear, especially since they are lost during the purification procedure (Fig 3B) . They possibly derive from premature termination of translation. The predicted molecular weight of the proteins translated from the various initiation sites were in good agreement with that of the main bands found by immunoblot analysis (Fig. 4 Lower).
The purified proteins (Fig. 3A) were further identified by amino-terminal sequence analysis. Both proteins of Mr 99,000 and Mr 89,000 were analyzed through 10 cycles of the sequencing apparatus. Two sequences from the Mr 99,000 protein were detected with an intensity relation of 1:2. The first starts with a possible Met-Glu-Lys and continues with Ile-Glu-Lys-Gly-Gln-Val. The second reads Lys-MetVal-Asp-Pro-Glu-Lys-Pro-Glu. The Mr 89,000 protein also contains two sequences with a molar ratio of 1:1. One starts with Met-Asp-Glu-Val-Ala-Lys-Lys-Lys-Ser-Lys and the other with Ala-Lys-Lys-Lys-Ser-Lys-Glu-Lys-Asp. Apart from the uncertainty in the first three amino acids, these sequences correspond to proteins beginning exactly at position 298 and 337 as well as 559 and 571 in the pADPRT cDNA (Fig. 1) . In the case of the sequence starting at position 559, a GTG trinucleotide coding for valine represents the initiation site. The fact that valine could be excluded in this position by -58
Biochemistry: Herzog et al. amino acid analysis is an unambiguous proof that additional initiation sites were used in the pADPRT cDNA. The sequences that do not begin with methionine probably derive from specific proteolytic degradation. Therefore, the appearance of a mixture of pADPRT-specific proteins in purified recombinant pADPRT activity is not only due to proteolytic degradation in E. coli but also is caused by usage of translation initiation signals located internally in the coding region of pADPRT cDNA.
Expression of a full-length pADPRT cDNA clone in E. coli probably would also show several proteins after induction. To get only one fusion protein, it is probably necessary to eliminate these internal translation start sites by site-directed mutagenesis. Additionally, these proteins can be isolated in large quantities in comparison to natural sources, which makes crystallization attempts and elucidation of the tertiary structure easier. Since crystallization of proteins usually
